

Datasheet: HCA399

Description:	HUMAN ANTI OCRELIZUMAB
Specificity:	OCRELIZUMAB
Other names:	Ocrevus
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD47395ia
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (lambda light chain) selected from Bio-Rad's human antibody phage display libraries. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Ocrelizumab

Specificity

Human Anti-Ocrelizumab Antibody, clone AbD47395ia is a paratope specific, inhibitory, anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug ocrelizumab, and its biosimilar products. It does not recognize the drug target, the B cell surface marker CD20, nor ocrelizumab in complex with CD20. This antibody can be used to measure free ocrelizumab levels in serum from patients.

Clone AbD47395ia (HCA399) is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 25.6nM and is one of the three antibodies offered for ADA assays. Antibody [HCA400](#) has an affinity of <0.001nM and [HCA401](#) has an affinity of 0.7nM.

Ocrelizumab (trade name Ocrevus) is a humanized monoclonal antibody of the IgG1/kappa isotype developed from the monoclonal antibody drug rituximab. Ocrelizumab targets the B cell surface marker CD20. Binding of the drug to its target triggers cell death through a number of mechanisms, including apoptosis, complement activation and cell-mediated cytotoxicity. In vivo, ocrelizumab selectively and effectively depletes CD20 expressing B cells, hence acting as an immunosuppressive drug.

Ocrelizumab is used in the treatment of primary progressive multiple sclerosis and relapsing forms of multiple sclerosis in adults.

[View a summary of all anti-ocrelizumab antibodies.](#)

Affinity

The monovalent intrinsic affinity of Human anti-Ocrelizumab Antibody, clone AbD47395ia was measured as $K_D = 25.6 \text{ nM}$ by real time, label-free molecular interaction analysis on immobilized ocrelizumab.

ELISA

This product may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera together with [HCA400](#) and [HCA401](#).

Storage

This product is shipped refrigerated.
When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.

Guarantee

12 months from date of despatch

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

Ocrevus is a registered trademark of Genentech/ Roche and Biogen.

Rituxan is a registered trademark of Genentech and Biogen.

Health And Safety Information

Material Safety Datasheet documentation #10040 available at:
<https://www.bio-rad-antibodies.com/SDS/HCA399>
10040

Licensed Use

For *in vitro* research purposes and for commercial applications for the provision of *in vitro*

testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI OCRELIZUMAB \(HCA400\)](#)

[HUMAN ANTI OCRELIZUMAB \(HCA401\)](#)

[HUMAN ANTI OCRELIZUMAB \(TZA044\)](#)

[HUMAN ANTI OCRELIZUMAB \(TZA045\)](#)

[HUMAN ANTI OCRELIZUMAB:HRP \(TZA045P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M430306:240503'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)